Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting histone deacetylases in T-cell lymphoma

4 Nov 2016

Abstract excerpt

Histone deacetylase inhibitors (HDACi) are epigenetic modifiers with single-agent activity in patients with cutaneous and peripheral T-cell lymphoma (CTCL, PTCL). The mechanisms for this preferential activity remain unclear, and although some would term this as 'class effect,' there are differences in efficacy and safety, likely a result of the varying chemical structures/classes, histone and non-histone targets,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Histone Deacetylase Inhibitors Research
Share to Lymphoma Diagnosis and Treatment
Share to T-cell and Retrovirus Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 27813438
DOI: 10.1080/10428194.2016.1247956

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting histone deacetylases in T-cell lymphomaPMID 27813438Read ↗

Histone Deacetylase Inhibitors for Peripheral T-cell Lymphomas: From Biology to Real-World TherapySemantic proximity Read ↗

Targeting histone deacetyalses in the treatment of B- and T-cell malignanciesSemantic proximity Read ↗

Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumorsSemantic proximity Read ↗

Epigenetics in the Pathogenesis and Treatment of Cutaneous T-Cell LymphomaSemantic proximity Read ↗

HDAC inhibitors in cancer biology: emerging mechanisms and clinical applicationsSemantic proximity Read ↗

Development of chidamide for peripheral T-cell lymphoma, the first orphan drug approved in ChinaSemantic proximity Read ↗

Electrocardiographic studies of romidepsin demonstrate its safety and identify a potential role for K(ATP) channel.Semantic proximity Read ↗

Romidepsin for the treatment of cutaneous T-cell lymphomaSemantic proximity Read ↗

Histone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer AgentsSemantic proximity Read ↗

Targeting epigenetic regulators in the treatment of T-cell lymphoma.Semantic proximity Read ↗

HDAC and HDAC Inhibitor: From Cancer to Cardiovascular DiseasesSemantic proximity Read ↗

SIRT1 is upregulated in cutaneous T-cell lymphoma, and its inhibition induces growth arrest and apoptosisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.